A Novel Missense Mutation in the *EDAR* Gene and One Missense Mutation in *EDA* Gene in the Study of HED Patients in Iran

Atefe Papi¹, Saeedreza Khatami^{1,*}, Hamid Galehdari¹ and Gholamreza Shariati²

¹Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

²Jondishapour University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran. Email: srkhatami@yahoo.com

Received 2020 September 29; Revised 2021 July 11; Accepted 2021 September 24.

Abstract

Hypohidrotic ectodermal dysplasia (HED) is the most common type of ectodermal dysplasia that is the result of faulty ectodermal development leading to such ectodermal defects as hypotrichosis, anodontia or hypodontia, and hypohidrosis or anhidrosis. X-linked HED is caused by mutations in ectodysplasin A (*EDA*) gene and accounts for 90% of all HED cases. Autosomal HED is caused by mutations in other involved genes, such as *EDA*-receptor (*EDAR*) gene. In this study, we included two distinct families with three HED patients. We collected 5 mL of peripheral blood from the probands, associated parents, and 120 matched unrelated controls (from related ethnicity) without any ectodermal disorder. DNA was extracted using the routine salting-out protocol from blood leukocytes. Polymerase chain reaction (PCR) purification and bidirectional Sanger sequencing of the PCR products were performed. We identified p.R156H (c.467 G > A) mutation in *EDA* gene in two affected brothers and their carrier mother (family 1) and a novel missense mutation c.1210G > A (p.A404T) in *EDAR* gene in a 4-year-old affected boy and his heterogeneous parents (family 2). Clinical evaluation, genetic findings, and bioinformatic analysis supported deleterious effects of both identified mutations on the *EDA* and *EDAR* gene products, which should be considered in genetic assessment of HED cases in Southwest of Iran.

Keywords: Hypohidrotic Ectodermal Dysplasia, *EDA*, *EDAR*, Missense Mutation

1. Background

Ectodermal dysplasia (ED) is a large heterogeneous group of inherited disorders characterized by ectodermal origin appendages defects (1, 2). Faulty ectodermal development leads to defects in ectoderm-derived structures such as hair, nails, teeth, and sweat glands. Hypohidrotic ectodermal dysplasia (HED) is the most common type of ED characterized by triad symptoms, including sparse hair (hypotrichosis), anodontia or hypodontia, and hypohidrosis or anhidrosis (3, 4). It also includes dryness of the skin, eye, and airways, maybe due to aplasia or hypoplasia of sebaceous glands and mucous membranes. The skin is thin and hypopigmented, whereas the skin around the eyes may be hyperpigmented (5-8). HED patients may seem prematurely aged due to wrinkled skin (9-11). Mental defectiveness reported in some groups could be the result of febrile seizures due to inability or insufficiency sweating, which could even threaten their lives in severe cases (12).

Mutations in ectodysplasin A (*EDA*) gene account for 90% of all HED cases and cause X-linked HED (13-15), while mutations in *EDA*-receptor (*EDAR*) and *EDAR*-associated death domain (*EDARADD*) genes cause rare autosomal

dominant and recessive forms. It was recently shown that other genes like tumor necrosis factor receptor associated factor 6 (TRAF6) and wingless-type MMTV integration site family, member 10A (WNT10A) could also be involved in causing HED (16, 17).

The prevalence of XL-HED is estimated at 1 in 100,000 live male births, and the carrier incidence is around 17.3 in 100,000 women (18).

The interaction between *EDA*, *EDAR*, and *EDARADD*, which are ligand, receptor, and protein adaptor, respectively, results in normal triggering of *EDA*-*EDAR* signaling pathway. Deficiencies in the *EDA*-*EDAR* signaling pathway cause HED (19).

EDA gene, which encodes ectodysplasin, consists of eight exons and is located on long arm of chromosome X (Xq12-q13.1). The two longest isoforms of *EDA* are ectodysplasin-A1 and -A2, which differ by an insertion of two amino acids. *EDA*-A1 binds only to *EDAR*, while *EDA*-A2 isoform employs X-linked *EDA* receptor (*XEDAR*) (3). *EDA*-A1 is a type II transmembrane protein with 391 amino acids and a TNF superfamily member involved in primary mesenchyme-epithelial interactions and regulates the de-

velopment of ectodermal derivatives with the role of embryonic morphogenesis (20). A variety of mutations in the *EDA* gene have been identified as missense and nonsense mutations, as well as small deletions. More than 200 mutations have been reported for *EDA* gene, most of which are missense. About 80% of mutations identified in *EDA* are small changes that include point mutations and deletions. More than half of these mutations have been seen in exons 1, 3, and 5 (1).

EDAR is a type I transmembrane receptor protein with 448 amino acids which belongs to TNF receptor superfamily and consists of an extracellular region (in N terminal), a transmembrane region, and a death domain in the intracellular region (in C terminal) (11, 19). *EDAR* gene is composed of 12 exons and located in chromosome 2 (2q11-q13). To date, more than 50 mutations have been identified in *EDAR* gene. Most of these mutations occur in exon 12, where death domain is located (<http://www.hgmd.cf.ac.uk/>).

2. Objectives

In this study, we investigated two distinct families with HED in southwest of Iran. Accordingly, for the first time, we identified the same mutations in *EDA* gene in two affected brothers in family 1 and a novel mutation in *EDAR* gene in an affected boy in family 2.

3. Methods

In this study, HED patients referred to Narges lab Ahvaz, Iran, in 2017 were included after clinical examination by specialists. All patients were diagnosed as HED cases based on having at least two of the three ectodermal abnormalities of teeth, hair, and sweat glands. We studied three HED patients in two distinct families in the southwest of Iran to assess gene mutations in the *EDA* and *EDAR* genes. Moreover, 120 healthy individuals were recruited as normal controls to rule out genetic polymorphism.

In this study, 5 mL of peripheral blood was collected from the probands, associated parents, and 120 matched unrelated controls (from related ethnicity) without any ectodermal disorder. DNA was extracted using the routine salting-out protocol from blood leukocytes. Primer sequences for all exons of *EDA* (NM_001399.4) and *EDAR* (NM_022336.3) and flanking intronic sites of *EDA* and *EDAR* were designed using Oligo 6.0 (Tables 1 and 2).

Polymerase chain reaction (PCR) was performed for *EDA* and *EDAR* genes with 80 - 90 ng genomic DNA, 12.5 μ L Master Mix (Amplicon Co.), and 1 μ L of each primer. The amplification condition for each PCR reaction of *EDA* was 95°C for 5 min, followed by 35 cycles of 95°C for 1 min, the

indicated annealing temperature for 30 s, and 72°C for 45 s, with a final extension at 72°C for 5 min. The amplified PCR fragments were separated on 1% agarose gels. Both DNA strands were sequenced using the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems 3500 DNA Analyzer). Finally, chromatograms were read and analyzed by Chromas and DNA Baser v4 software.

4. Results

In this study, two families with three patients were included. Family 1 was an Arab family, which had two affected sons with clinical features suggestive of HED, including deformity of teeth, hair sparseness, and heat intolerance; this family was tested for *EDA* mutation. Family 2 was a consanguineous Persian family (first cousins) who had an affected boy with teeth abnormality, heat intolerance, and skin dryness symptoms; this family was tested for *EDAR* mutation.

In family 1, *EDA* gene was investigated for mutation in two affected brothers and their mother. The same mutation of *EDA* gene was observed in two brothers and their asymptomatic carrier mother. Sequencing all the exons of *EDA* gene in family 1 revealed p.R156H (c.467G > A) mutation in exon 2 of *EDA* gene (Figure 1).

In family 2, a 4-year-old boy affected with HED symptoms and his parents were investigated for mutation. After ruling out the presence of mutations in *EDA*, the *EDAR* gene remained as one of the main candidate genes linked to the disease to date. Sequence analysis of entire coding exons and the flanking intronic regions of the *EDAR* gene revealed one novel mutation c.1210G > A (p.A404T) in exon 12, where death domain is located (Figure 2).

5. Discussion

EDA/EDAR pathway plays a crucial role in the development of many ectodermal organs in the embryonic stage. Mutations in genes encoding major components of the *EDA/EDAR* pathway disrupt normal ectodermal morphogenesis and lead to different forms of ED, which are indistinguishable with clinical signs examinations (6, 8).

In most HED cases, mutations in two main genes cause this disorder. The *EDAR* gene mutation results in autosomal dominant or recessive forms of HED, while mutations in *EDA* gene are responsible for X-linked HED, accounting for 90% of all HED cases (6).

EDA is a member of the tumor necrosis factor (TNF) superfamily, that can be cleaved in stalk region by furin to produce a secreted form to be ligand of *EDAR* (11). Therefore, furin cleavage sites in the stalk region are required for the *EDA*-mediated cell-to-cell signaling that regulates the

Table 1. Primers Used for the Amplification of the *EDAR* Gene

Primer	Sequence	Primer	Sequence
<i>EDAR-E1-1-F</i>	TAGCACTCCCACGCCTAAAG	<i>EDAR-E5-1-F</i>	CTGCACTCACCTGTGTCCC
<i>EDAR-E1-1-R</i>	GAGGTCAGCTTCAGTCCCAG	<i>EDAR-E5-1-R</i>	GCAGTATCCATGACCCCTGT
<i>EDAR-E1-2-F</i>	TACCTGCTTCTGAGAGGGCT	<i>EDAR-E6-1-F</i>	GCTGTCCAGCTCACCTGTCT
<i>EDAR-E1-2-R</i>	GGCCACAGCTGAAGAGTTTAG	<i>EDAR-E6-1-R</i>	CGTGCTGAACAAATACCGTG
<i>EDAR-E2-1-F</i>	CTGCAGAGTAGGAGGCACG	<i>EDAR-E7-1-F</i>	CAGCGTCTTTGAAGGTGGAG
<i>EDAR-E2-1-R</i>	ATGACGTGAAGAGGCGGTAA	<i>EDAR-E7-1-R</i>	GCTTTCATCCGAGTACCACC
<i>EDAR-E3-1-F</i>	ATAAAGGTAGCCAGACCCCC	<i>EDAR-E8-1-F</i>	TCCTGAGCTCTGGGTCTTC
<i>EDAR-E3-1-R</i>	AGAGGCCAAGAAACAGTCCA	<i>EDAR-E8-1-R</i>	GTGAGAGCAGAAGCAGCGAG
<i>EDAR-E4-1-F</i>	GGGTCTTGCAGGAGTCACAT	<i>EDAR-E9-1-F</i>	CAGAGCCATGAGCCAATTCT
<i>EDAR-E4-1-R</i>	ACAATGCCACAAGCAGGAG	<i>EDAR-E9-1-R</i>	TGCTCAGGATCCACAGGAC
<i>EDAR-E10-1-F</i>	TGGACAAGTTCACACAGGA		
<i>EDAR-E10-1-R</i>	GAGCCACATCTCACAGCTCA		
<i>EDAR-E11-1-F</i>	CCCCTTTCTGGAGATGAAAA		
<i>EDAR-E11-1-R</i>	CTCAGTTCCTCTACAGGAG		
<i>EDAR-E12-1-F</i>	TTGACTGTGACTTGAACATCT		
<i>EDAR-E12-1-R</i>	CAGTCTTTGGCACCCTCA		

Table 2. Primers Used for the Amplification of the *EDA* Gene

Primer	Sequence	Primer	Sequence
<i>EDA_E1_1-F</i>	GCAGAGGCCAACCTCAC	<i>EDA_E10_1-F</i>	TTGGGGAAATCTCATGGAT
<i>EDA_E1_1-R</i>	CGCAACTCTAGGTAGCAGCA	<i>EDA_E10_1-R</i>	TTGTTTTATAAGCCAATGTTTGT
<i>EDA_E2_1-F</i>	GGGCTATTGGAGTATGTTCT	<i>EDA_E11_1-F</i>	GGCTATGACTGAGTGGGGTC
<i>EDA_E2_1-R</i>	AGATCCACCTCCCTAAAAA	<i>EDA_E11_1-R</i>	GCACAGTCTCAGCTCACTGC
<i>EDA_E3_1-F</i>	TTGGGACTTTGGAGGTGTTT	<i>EDA_E12_1-F</i>	TCTTGGGGATCCCTCCTAGT
<i>EDA_E3_1-R</i>	CCACGTGGTTAAGGCTCTTC	<i>EDA_E12_1-R</i>	ATACAAAAATCGACTCTTGATT
<i>EDA_E4_1-F</i>	TGAATGACAGACTTGCTGGG	<i>EDA_E13_1-F</i>	AGCAGGACTCCGTCTCAAAA
<i>EDA_E4_1-R</i>	TCATCAAAGTGTCAAAGTCAAAGA	<i>EDA_E13_1-R</i>	GCTCTCAGGATCACCCACTC
<i>EDA_E5_1-F</i>	TGCTGCAAAGTTAATGTCCA	<i>EDA_E14_1-F</i>	TTATGCCCTCTGATTGTCCT
<i>EDA_E5_1-R</i>	AAAAATGGATCAGACCTAAATG	<i>EDA_E14_1-R</i>	GAAACCGTCAGAATCTCCG
<i>EDA_E6_1-F</i>	TCATGGCCTTCTTCTAAGTT	<i>EDA_E15_1-F</i>	GATGGAACATGGGACTGGT
<i>EDA_E6_1-R</i>	AAGTGGCAGAGTGTGGTA	<i>EDA_E15_1-R</i>	ATTATTGGAGGCTGGGGAG
<i>EDA_E7_1-F</i>	TTCCTCAGTCCAGTACTCTTCATC	<i>EDA_E16_1-F</i>	GGGGTTGTGAATCCTTGGT
<i>EDA_E7_1-R</i>	TCTCAAAAACAGTAAAGGGAA	<i>EDA_E16_1-R</i>	CCGGATCTGATTCTGGATA
<i>EDA_E8_1-F</i>	GCCAGCATTTGGTTCTGAAGT	<i>EDA_E17_1-F</i>	TCTCTCCCAATCCCTTCT
<i>EDA_E8_1-R</i>	TGTCAACGGAAAGTTATCTGTGTT	<i>EDA_E17_1-R</i>	TTGTCAACCCTGGAGTCACTG
<i>EDA_E9_1-F</i>	CCCCAATTCATACCAGCTA		
<i>EDA_E9_1-R</i>	TGTCAATGGTAAACCTGCGA

Figure 1. A and B, *EDA* gene sequencing results show a (CGC > CAC) missense mutation on *EDA* gene leading to X-linked disorder in two brothers; C, a heterozygous change in carrier mother

ectodermal appendages development, as reported before (8).

In this study, we investigated the sequence analysis of *EDA* gene, the main gene involved in XHED, in two affected brothers and their carrier mother. The results in family 1 (with unrelated parents) revealed a previously reported missense mutation, G to A nucleotide substitution at codon 156 in exon 2 of *EDA* gene [p.R156H (c.467G > A)] at the furin cleavage site, which is a key consensus position site.

To date, more than 200 mutations have been reported for the *EDA* gene, most of which are missense, mostly seen in exons 1, 3, and 5 (1).

Regarding *EDAR*, which is the gene involved in autosomal

form of HED, we identified an unreported missense mutation in the affected boy (homozygous) and his consanguineous parents (heterozygous) in family 2. *EDAR* is a type I transmembrane receptor protein with 448 amino acids. This protein belongs to TNF superfamily and consists of an extracellular region (in N terminal), a transmembrane region, and a death domain in the intracellular region (in C terminal). Previous studies showed that extracellular domain is necessary for binding to *EDA* ligand (8).

Our results showed that nucleotide substitution (c.1210G > A (p.A404T) - GCA > ACA) causes amino acid alanine (A) to change to threonine (T) in *EDAR* protein, where death domain is located.

Threonine is larger than alanine and more polarized

Figure 2. A, *EDAR* gene sequencing results show the same heterozygous GCA > ACA change in the parents; B, homozygous (GCA > ACA) missense in the case of patient; C, control healthy samples were entirely homozygous for wild type allele.

with different tendencies for α helix formation. Not surprisingly, this change may affect the function of the protein. To date, over 50 mutations have been identified in this gene, of which 34 mutations are missense. Most of these mutations occur in exon 12, where death domain is located.

To confirm our findings, 120 unrelated healthy controls were selected and studied by Sanger sequencing to rule out genetic polymorphism. As mentioned earlier, the healthy control samples were entirely homozygous for wild type alleles so that the changes would not be a polymorphism.

For more reassurance, we used the mentioned bioinformatics tools to predict pathogenicity of novel detected mutation and their impact on *EDAR* functions. We used I-Mutant tool to predict the change of protein stability. I-Mutant tool predicted the effect of mutation on the protein as “decreased stability”. Sorting intolerant from toler-

ant (SIFT) has been used to human variants and is able to distinguish disease causing mutations from neutral polymorphisms. In our study, SIFT predicted the mutation as “damaging”. We also applied Polyphen-2, which predicts based on several parameters like phylogenetic, structural features, and sequence of protein. Polyphen-2 evaluated the potential of the alteration as “probably damaging”. In addition, Mutation taster was used to study the effects of missense mutations on disease-causing potential of sequence changes. Not surprisingly, the software predicted the impact of identified variant as “disease causing” (21).

Accordingly, all clinical evaluations, genetic findings, and computational analysis in this study supported the deleterious effects of both mutations on the *EDA* and *EDAR* genes. These findings can help to identify the exact genetic cause of these disorders in our population, and they might

be useful for further studies and screening in different populations.

Acknowledgments

The authors wish to thank the staff of Narges Genetic Laboratory and all the patients and their families.

Footnotes

Authors' Contribution: SRK, GRSH, and HG designed the study and wrote the protocol. AP managed the analyses of the study and wrote the first draft of the manuscript. All authors discussed the results and contributed to the final manuscript.

Conflict of Interests: The authors declare no conflict of interests.

Ethical Approval: This study was approved by the Ethics Committee of Genetics Department of Shahid Chamran University of Ahvaz, Iran (code: EE/99.3.02.39641/scu.ac.ir).

Funding/Support: This study was partially granted by Shahid Chamran University of Ahvaz (No. 16670).

Informed Consent: An informed consent was obtained from all participants.

References

- Garcia-Martin P, Hernandez-Martin A, Torrelo A. Ectodermal dysplasias: A clinical and molecular review. *Actas Dermosifiliogr*. 2013;**104**(6):451-70. doi: [10.1016/j.ad.2012.07.012](#). [PubMed: [23103118](#)].
- Singh GP, Saxena V. Hypohidrotic Ectodermal Dysplasia. *Med J Armed Forces India*. 2015;**71**(Suppl 2):S530-3. doi: [10.1016/j.mjafi.2014.05.006](#). [PubMed: [26843773](#)]. [PubMed Central: [PMC4705176](#)].
- Mikkola ML. Molecular aspects of hypohidrotic ectodermal dysplasia. *Am J Med Genet A*. 2009;**149A**(9):2031-6. doi: [10.1002/ajmg.a.32855](#). [PubMed: [19681132](#)].
- Torkamandi S, Gholami M, Mohammadi-Asl J, Rezaie S, Zaimy MA, Omrani MD. A Novel Splice-site Mutation in the EDAR Gene Causes Severe Autosomal Recessive Hypohidrotic (Anhidrotic) Ectodermal Dysplasia in an Iranian Family. *Int J Mol Cell Med*. 2016;**5**(4):260-3. [PubMed: [28357203](#)]. [PubMed Central: [PMC5353988](#)].
- Jones KB, Goodwin AF, Landan M, Seidel K, Tran DK, Hogue J, et al. Characterization of X-linked hypohidrotic ectodermal dysplasia (XL-HED) hair and sweat gland phenotypes using phototrichogram analysis and live confocal imaging. *Am J Med Genet A*. 2013;**161A**(7):1585-93. doi: [10.1002/ajmg.a.35959](#). [PubMed: [23687000](#)]. [PubMed Central: [PMC4414120](#)].
- Kowalczyk-Quintas C, Schneider P. Ectodysplasin A (EDA) - EDA receptor signalling and its pharmacological modulation. *Cytokine Growth Factor Rev*. 2014;**25**(2):195-203. doi: [10.1016/j.cytogfr.2014.01.004](#). [PubMed: [24508088](#)].
- Wright JT, Grange DK, Fete M, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, et al., editors. *Hypohidrotic Ectodermal Dysplasia*. Washington, USA: GeneReviews; 1993.
- Goyal M, Pradhan G, Gupta S, Kapoor S. Hypohidrotic ectodermal dysplasia with ankylosis of temporomandibular joint and cleft palate: A rare presentation. *Contemp Clin Dent*. 2015;**6**(1):110-2. doi: [10.4103/0976-237X.149304](#). [PubMed: [25684924](#)]. [PubMed Central: [PMC4319327](#)].
- Liu G, Wang X, Qin M, Sun L, Zhu J. A novel splicing mutation of ectodysplasin A gene responsible for hypohidrotic ectodermal dysplasia. *Oral Dis*. 2018;**24**(6):1101-6. doi: [10.1111/odi.12874](#). [PubMed: [29676859](#)].
- Ladda R, Gangadhar S, Kasat V, Bhandari A. Prosthodontic management of hypohidrotic ectodermal dysplasia with anodontia: A case report in pediatric patient and review of literature. *Ann Med Health Sci Res*. 2013;**3**(2):277-81. doi: [10.4103/2141-9248.113679](#). [PubMed: [23919206](#)]. [PubMed Central: [PMC3728879](#)].
- Trzeciak WH, Koczorowski R. Molecular basis of hypohidrotic ectodermal dysplasia: An update. *J Appl Genet*. 2016;**57**(1):51-61. doi: [10.1007/s13353-015-0307-4](#). [PubMed: [26294279](#)]. [PubMed Central: [PMC4731439](#)].
- Anoop TM, Simi S, Mini PN, Ramachandran M, Jabbar PK, Rajakumari PK, et al. Hypohidrotic ectodermal dysplasia. *J Assoc Physicians India*. 2008;**56**:268-70. [PubMed: [18702393](#)].
- Chassaing N, Cluzeau C, Bal E, Guigue P, Vincent MC, Viot G, et al. Mutations in EDARADD account for a small proportion of hypohidrotic ectodermal dysplasia cases. *Br J Dermatol*. 2010;**162**(5):1044-8. doi: [10.1111/j.1365-2133.2010.09670.x](#). [PubMed: [20222921](#)].
- Cluzeau C, Hadj-Rabia S, Jambou M, Mansour S, Guigue P, Masmoudi S, et al. Only four genes (EDA1, EDAR, EDARADD, and WNT10A) account for 90% of hypohidrotic/anhidrotic ectodermal dysplasia cases. *Hum Mutat*. 2011;**32**(1):70-2. doi: [10.1002/humu.21384](#). [PubMed: [20979233](#)].
- Salas-Alanis JC, Wozniak E, Mein CA, Duran McKinster CC, Ocampo-Candiani J, Kelsell DP, et al. Mutations in EDA and EDAR Genes in a Large Mexican Hispanic Cohort with Hypohidrotic Ectodermal Dysplasia. *Ann Dermatol*. 2015;**27**(4):474-7. doi: [10.5021/ad.2015.27.4.474](#). [PubMed: [26273176](#)]. [PubMed Central: [PMC4530170](#)].
- Haghighi A, Nikuei P, Haghighi-Kakhki H, Saleh-Gohari N, Baghestani S, Krawitz PM, et al. Whole-exome sequencing identifies a novel missense mutation in EDAR causing autosomal recessive hypohidrotic ectodermal dysplasia with bilateral amastia and palmoplantar hyperkeratosis. *Br J Dermatol*. 2013;**168**(6):1353-6. doi: [10.1111/bjd.12151](#). [PubMed: [23210707](#)].
- Deshmukh S, Prashanth S. Ectodermal dysplasia: A genetic review. *Int J Clin Pediatr Dent*. 2012;**5**(3):197-202. doi: [10.5005/jip-journals-10005-1165](#). [PubMed: [25206167](#)]. [PubMed Central: [PMC4155886](#)].
- Mortier K, Wackens G. Ectodermal dysplasia anhidrotic. *Orphanet Encyclopedia*. 2004;**3**:1-6.
- Chen Y, Molloy SS, Thomas L, Gambee J, Bachinger HP, Ferguson B, et al. Mutations within a furin consensus sequence block proteolytic release of ectodysplasin-A and cause X-linked hypohidrotic ectodermal dysplasia. *Proc Natl Acad Sci U S A*. 2001;**98**(13):7218-23. doi: [10.1073/pnas.131076098](#). [PubMed: [11416205](#)]. [PubMed Central: [PMC34649](#)].
- Franzke CW, Bruckner P, Bruckner-Tuderman L. Collagenous transmembrane proteins: Recent insights into biology and pathology. *J Biol Chem*. 2005;**280**(6):4005-8. doi: [10.1074/jbc.R400034200](#). [PubMed: [15561712](#)].
- Walters-Sen LC, Hashimoto S, Thrush DL, Reshmi S, Gastier-Foster JM, Astbury C, et al. Variability in pathogenicity prediction programs: Impact on clinical diagnostics. *Mol Genet Genomic Med*. 2015;**3**(2):99-110. doi: [10.1002/mgg3.116](#). [PubMed: [25802880](#)]. [PubMed Central: [PMC4367082](#)].